Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers
2010

FBI-1's Role in Ovarian Cancer

Sample size: 220 publication Evidence: moderate

Author Information

Author(s): Jiang Li, Siu Michelle KY, Wong Oscar GW, Tam Kar Fai, Lam Eric W-F, Ngan Hextan YS, Le Xiao-Feng, Wong Esther SY, Chan Hoi Yan, Cheung Annie NY

Primary Institution: The University of Hong Kong

Hypothesis

FBI-1 activates membrane type 1-matrix metalloproteinase (MT1-MMP) and is associated with poor outcomes in ovarian cancer.

Conclusion

FBI-1 promotes ovarian cancer cell proliferation, mobility, and invasiveness, making it a potential target for chemotherapy.

Supporting Evidence

  • FBI-1 was significantly overexpressed in 73.8% of ovarian cancer cases.
  • Higher FBI-1 expression correlated with advanced cancer stages and poor survival rates.
  • FBI-1 enhanced cell migration and invasion in ovarian cancer cell lines.

Takeaway

FBI-1 is a protein that helps ovarian cancer cells move and grow, and having more of it is linked to worse outcomes for patients.

Methodology

The study involved analyzing clinical samples and cell lines for FBI-1 expression and its effects on cancer cell behavior.

Limitations

The study does not establish FBI-1 as an independent predictor of survival.

Participant Demographics

Included 220 archival clinical samples from ovarian cancer patients, with ages ranging from 20 to 78 years.

Statistical Information

P-Value

P = 0.012 for advanced stage association, P = 0.032 for overall survival, P = 0.016 for disease-free survival.

Confidence Interval

95% CI = 0.971-1.089 for overall survival.

Digital Object Identifier (DOI)

10.1186/1476-4598-9-318

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication